LOTEMAX GEL
Total Payments
$3.5M
Transactions
9,290
Doctors
4,462
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $580,769 | 4,360 | 2,552 |
| 2017 | $2.9M | 4,930 | 2,859 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 232 | 72.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $286,500 | 99 | 8.3% |
| Food and Beverage | $236,066 | 8,505 | 6.8% |
| Charitable Contribution | $230,129 | 7 | 6.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $94,940 | 59 | 2.7% |
| Consulting Fee | $61,425 | 28 | 1.8% |
| Travel and Lodging | $51,870 | 203 | 1.5% |
| Education | $1,153 | 157 | 0.0% |
Payments by Type
Research
$2.5M
232 transactions
General
$962,083
9,058 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38 BID and TID versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | Valeant Pharmaceuticals North America LLC | $1.7M | 9 |
| Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel, 0.38, in Normal Healthy Volunteers | Valeant Pharmaceuticals North America LLC | $356,600 | 1 |
| A PHASE 3, MULTI-CENTER, DOUBLE-MASKED, VEHICLE-CONTROLLED, RANDOMIZED, PARALLEL-GROUP STUDY TO ASSESS LOTEPREDNOL ETABONATE OPHTHALMIC GEL, 0.38 BID AND TID VERSUS VEHICLE GEL FOR THE TREATMENT OF OCULAR INFLAMMATION AND PAIN FOLLOWING CATARACT SURGERY | Bausch Health US, LLC | $273,118 | 6 |
| A Randomized, Multicenter, Double Masked, Parallel-Group Study Assessing the Safety and Efficacy of Loteprednol Etabonate Ophthalmic Gel, 0.5 versus Prednisolone Acetate Ophthalmic Suspension, 1 for the Treatment of Intraocular Inflammation Following Surgery for childhood Cataract. | Valeant Pharmaceuticals North America LLC | $58,391 | 0 |
| Long Term Effects of Topical Loteprednol Etabonate Use in Dry Eye Patients | Valeant Pharmaceuticals North America LLC | $45,000 | 0 |
| A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients with Treatments to Optimize the Ocular Surface before Implantation | Valeant Pharmaceuticals North America LLC | $23,110 | 0 |
| A Randomized, Multicenter, Double Masked, Parallel-Group Study Assessing the Safety and Efficacy of Loteprednol Etabonate Ophthalmic Gel, 0.5 versus Prednisolone Acetate Ophthalmic Suspension, 1 for the Treatment of Intracocular Inflammation Following Sugery for Childhood Cataract | Bausch Health US, LLC | $6,500 | 0 |
Top Doctors Receiving Payments for LOTEMAX GEL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Norma Bowyer | — | Morgantown, WV | $2.0M | 214 |
| , M.D. INC | Retina Specialist | Inglewood, CA | $143,727 | 3 |
| , MD | Ophthalmology | Rancho Cordova, CA | $111,249 | 9 |
| , M.D | Ophthalmology | Murrieta, CA | $105,698 | 5 |
| , MD | Ophthalmology | Tamarac, FL | $93,881 | 5 |
| , OD | Optometrist | Seneca, PA | $68,167 | 1 |
| , MD | Ophthalmology | Great Falls, MT | $65,122 | 1 |
| , MD | Ophthalmology | Cincinnati, OH | $48,839 | 1 |
| , M.D | Ophthalmology | Houston, TX | $34,084 | 42 |
| , M.D | Ophthalmology | Columbus, OH | $28,449 | 12 |
| , MD | Ophthalmology | Birmingham, AL | $27,468 | 3 |
| , M.D | Specialist | El Paso, TX | $24,991 | 4 |
| , MD | Ophthalmology | Colton, CA | $21,682 | 37 |
| , MD | Ophthalmology | Santa Barbara, CA | $19,954 | 29 |
| , MD | Ophthalmology | Miami, FL | $16,992 | 15 |
| , MD | Ophthalmology | Lake Villa, IL | $15,754 | 24 |
| , MD | Ophthalmology | Newport Beach, CA | $15,071 | 26 |
| , MD | Ophthalmology | Monroeville, PA | $15,000 | 1 |
| , O.D | Optometrist | Concord, NC | $14,389 | 24 |
| , M.D | Ophthalmology | La Grange Highlands, IL | $13,758 | 19 |
| , MD | Ophthalmology | Los Angeles, CA | $11,944 | 3 |
| , M.D | Ophthalmology | Honolulu, HI | $11,625 | 13 |
| , MD | Ophthalmology | Poughkeepsie, NY | $11,531 | 4 |
| , MD | Ophthalmology | Germantown, TN | $10,217 | 19 |
| , M.D | Ophthalmology | Los Angeles, CA | $10,000 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 4,462
- Transactions 9,290
About LOTEMAX GEL
LOTEMAX GEL is a drug associated with $3.5M in payments to 4,462 healthcare providers, recorded across 9,290 transactions in the CMS Open Payments database. The primary manufacturer is Valeant Pharmaceuticals North America LLC.
Payment data is available from 2017 to 2018. In 2018, $580,769 was paid across 4,360 transactions to 2,552 doctors.
The most common payment nature for LOTEMAX GEL is "Unspecified" ($2.5M, 72.2% of total).
LOTEMAX GEL is associated with 7 research studies, including "A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38 BID and TID versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery" ($1.7M).